Biosimilars Loom Large As Sandoz Sets Stage For Spinoff
Capital Markets Days Highlight Off-Patent Biologics As Major Opportunity After Separation
At a pair of capital markets days in New York and London, Sandoz has set out expectations for its post-spinoff future – with biosimilars featuring heavily in the company’s growth plans.
